Timisoara

• Clinical Trial of Lenvatinib, Pembrolizumab, and Standard Chemotherapy for Head and Neck Squamous Cell Carcinoma That has Returned or Spread Ended
  2022-500820-31-00 4 2020-07-16 Recurrent or metastatic squamous cell carcinoma of the head and neck
• Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer Ended
  2023-503831-17-00 4 2019-12-23 The treatment of participants with HRRm and/or HRD-positive cancer
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal, Pancreatic, or Colorectal Cancer Ended
  2023-507148-35-00 5 2019-10-03 Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastroint
• Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLC Ended
  2023-508449-41-00 5 2019-06-26 Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
• Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC Ended
  2023-509774-40-00 5 2019-06-25 Stage IV lung cancer condition
• A study evaluating the efficacy and safety of ralinepag in treatment of patients with pulmonary arterial hypertension. Ended
  2023-509304-16-00 5 2019-05-16 Pulmonary arterial hypertension (PAH)
• Pembrolizumab as adjuvant therapy for resectable high-risk LA cSCC Ended
  2022-500395-57-00 5 2019-03-04 Resectable high-risk Locally Advanced Cutaneous Squamous Cell Carcinom
• The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the treatment of ulcerative colitis (UC) Ended
  2024-514815-92-00 5 2015-07-16 Ulcerative colitis
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api
• A trial to show the similarity in effects, safety and immune response of FYB206 compared to Keytruda in people with metastatic non-squamous … Ended
  2023-509766-37-00 5 NSCLC

Showing 289–298 of 298 trials